This case report demonstrates that using a biologic extracellular matrix (ECM) envelope to "rehabilitate" an existing fibrotic implant pocket for cardiac electronic devices can lead to a new, healthy tissue layer. This approach shows promise for simplifying future device revisions and reducing complication risks associated with scar tissue.
What Problem Does This Paper Address?
Cardiac implantable electronic devices (CIEDs), like pacemakers and defibrillators, are often implanted in pockets within the body. Over time, the body's foreign body reaction can cause these pockets to become encased in dense, fibrous scar tissue. This scar tissue can make future procedures, such as generator replacements or lead revisions, significantly more difficult and increase the risk of complications like infection. While biologic ECM envelopes have shown benefits when used during initial CIED implantation (reducing fibrosis and improving lead mobility), their use in existing, already fibrotic pockets during revision surgery was not well-documented. This paper addresses the question of whether a biologic ECM envelope can successfully "rehabilitate" such a fibrotic pocket, making it more amenable to future interventions.
Methods
The core of this study is a single case report. A 73-year-old male patient required a revision surgery for his implantable cardioverter-defibrillator (ICD). During this procedure, the existing fibrotic pocket was partially cleared of scar tissue (partial capsulectomy). A new ICD was then placed inside a biologic ECM envelope (derived from porcine small intestine submucosa) and implanted into this prepared pocket. Five months later, the patient needed another reoperation. At this time, the researchers examined the pocket tissue histologically to assess the outcome of the ECM envelope implantation.
Datasets
Not discussed in the paper. This is a single case report with histological analysis of tissue samples from the patient.
Key Insights and Ideas
ECM envelopes can "rehabilitate" fibrotic pockets: The most significant finding is that a biologic ECM envelope, when placed within an existing fibrotic CIED pocket, can be replaced by a new, healthy layer of cellular and vascular tissue. This effectively "rehabilitates" the pocket.
Histology confirms tissue regeneration: The histological analysis provided crucial evidence, showing a thin, vascularized layer of host tissue replacing the dense fibrosis and the ECM envelope itself, which had been fully resorbed.
Simplifies future procedures: This regenerated tissue layer was soft and vascularized, allowing for easy mobilization of the device and leads during the subsequent reoperation, avoiding the need for further aggressive capsulectomy.
Partial capsulectomy may be sufficient: The authors suggest that even a partial removal of the fibrotic capsule might be enough to create an interface for the ECM envelope to promote this regenerative process, potentially avoiding the risks associated with full capsulectomy.
Key Results
Histological evidence of regeneration: Hematoxylin-eosin and Masson's trichrome staining confirmed a new pocket wall composed of cellular and vascular tissue with a thin collagenous lining, indicating successful remodeling of the ECM envelope into functional host tissue.
Absence of fibrosis and calcification: The generator and leads were found to be free of fibrosis and calcification during the second reoperation.
Simplified reoperation: The regenerated tissue facilitated easy generator and lead mobilization, reducing procedural difficulty and eliminating the need for further capsulectomy.
Long-term stability: The patient remained stable and uneventful at 3 years post-operation.
Limitations and Future Work
Single Case Report: The primary limitation is that this is a single case study, meaning the findings may not be generalizable to all patients.
Role of Partial Capsulectomy: The exact contribution of the partial capsulectomy performed during the first procedure to the successful regeneration is unclear. The authors hypothesize that it created a necessary interface, but further investigation is needed.
Future Investigations: The authors strongly advocate for larger clinical studies to further explore the regenerative potential and clinical benefits of using biologic ECM envelopes in existing fibrotic CIED pockets during revision procedures. They aim to validate these findings and understand the optimal conditions for this regenerative process.
Summary updated
Abstract
Cardiac implantable electronic device (CIED) implantation comes with a risk of hypovascular fibrosis from a foreign body reaction (FBR) to the generator and/or leads.1Maytin M. John R.M. Epstein L.M. Device Pocket Scar Predicts Transvenous Lead Extraction Difficulty.JICRM. 2015; 6: 2173-2177Crossref Google Scholar Biologic extracellular matrix (ECM) CIED envelopes have been shown to alter the FBR and lead to significantly less fibrous lead entrapment, easier generator and lead mobilization, less procedural difficulty, and thinner mature tissue capsules at reoperation compared to using no envelope at initial implantation.2Catanzaro J.N. Bilchick K.C. Christopher T.J. et al.Implanting Cardiovascular Electronic Devices with A Biologic Tissue Envelope Improves Healing and Facilitates Reoperative Procedures.Circulation. 2022; 146A11052Google Scholar However, limited clinical experience exists on the outcomes of implanting biologic envelopes within existing fibrotic capsules. We present a unique case which highlights our findings from placing a CIED within a biologic ECM envelope and implanting it within an existing fibrotic CIED capsule during a revision procedure. A 73-year-old immunocompetent male with no renal issues received an Implantable Cardioverter Defibrillator (ICD) during a changeout reoperative procedure in 2020 which included partial capsulectomy of the existing fibrotic pocket to remove portions of the capsule necessary to free the device and leads. At the time of surgery, he was not taking any antiplatelets or anticoagulants, aside from 325mg of aspirin daily. The patient received intravenous vancomycin prophylaxis 1hr prior to the procedure, the skin was prepared with chlorhexidine, and the wound was irrigated with antibiotic. To rehabilitate the existing fibrotic pocket, the new ICD was first placed into a biologic envelope derived from porcine small intestine submucosa extracellular matrix (SIS-ECM, CanGaroo® Envelope size Large, Aziyo Biologics Inc.) then implanted. Five months post-procedure, the patient experienced lead-related complications which resulted in the need for an additional reoperation. When the device pocket was reopened, a thin, soft vascularized capsule was visible lining the entire pocket, the generator and leads were free of fibrosis and calcification, and there was no gross visible remnant of the envelope (Figure 1a-b). A full-thickness anterior pocket wall biopsy was taken and sent for independent histopathology. Hematoxylin and eosin (H&E) and Masson’s trichrome staining confirmed no active inflammation, and a new pocket wall consisting of cellular and vascular tissue with a thin collagenous lining, which was consistent with fully remodeled extracellular matrix (ECM) envelope. No remnants of the previously implanted envelope were apparent in this sample. Where previous capsulectomy had been performed (Figure 2b, e), the new cellular and vascular pocket wall (arrows) was continuous with chest wall subcutaneous tissues (asterisks). Adjacent to that area within prior capsule remnant (where capsulectomy had not been performed) (Figure 2c, f, white dashes), there was a new cellular and vascular layer replacing the pocket lining (black arrows) which was in continuity with the surrounding subcutaneous tissues where capsulectomy had been performed (white arrow). The patient had an uneventful recovery and is still stable at 3 years post-op. This unique case provided an opportunity to evaluate the outcome of using a biologic ECM envelope within an existing fibrotic CIED device pocket. Implanted CIEDs frequently stimulate a foreign body reaction (FBR) within the host, leading to hypovascular fibrous capsule development surrounding the device and/or leads, potentially increasing reoperative difficulty and risk of major complications such as infection.1Maytin M. John R.M. Epstein L.M. Device Pocket Scar Predicts Transvenous Lead Extraction Difficulty.JICRM. 2015; 6: 2173-2177Crossref Google Scholar The observed increase in infection risk during reoperative procedures has been hypothesized to be due to the fibrous capsule acting as a nidus for infection by providing a protective barrier surrounding bacterial colonization on the device (introduced during the previous implantation procedure) from circulating immune cells until the capsule is disrupted.3Wilkoff B.L. Infections associated with cardiac implantable electronic devices are misunderstood.Tex Heart Inst J. 2011; 38: 353-354Google Scholar Patients expected to undergo multiple generator changes, upgrades, or revisions throughout life are especially impacted, as the risk of complications such as infection and hematoma increases with each additional procedure.4Kleemann T. Becker T. Strauss M. et al.Prevalence of bacterial colonization of generator pockets in implantable cardioverter defibrillator patients without signs of infection undergoing generator replacement or lead revision.Europace. 2010; 12: 58-63https://doi.org/10.1093/europace/eup334Crossref PubMed Scopus (53) Google Scholar Techniques that may mitigate the formation and/or persistence of dense fibrotic capsule tissue across procedures may alleviate this heightened risk of complications. Biologic ECM scaffolds are well-known for their tissue remodeling properties, which are due to intrinsic bioactive factors that recruit stem cells, promote angiogenesis, and modulate the host inflammatory response.5Brown B.N. Badylak S.F. Extracellular matrix as an inductive scaffold for functional tissue reconstruction.Transl Res. 2014; 163: 268-285https://doi.org/10.1016/j.trsl.2013.11.003Abstract Full Text Full Text PDF Scopus (324) Google Scholar Only naturally derived biologic materials, such as SIS-ECM, contain these regenerative molecules. In a recent pre-clinical study, animals with implanted biologic ECM envelopes encasing CIEDs had greater device stabilization and more vascularized capsules compared to implanting the device alone.6Deegan D. Piasecki S.K. Riebman J.B. An Acellular Biologic Extracellular Matrix Envelope for Cardiovascular Implantable Electronic Devices: Preclinical Evaluation.J Regen Med. 2022; 11: 5https://doi.org/10.4172/2325-9620.1000226Crossref Google Scholar These results also translate to the clinic: interim results from the HEAL Study (ClinicalTrials.gov #NCT04645173) indicate that the use of biologic ECM envelopes during initial device implantation can significantly reduce fibrous lead entrapment and simplify reoperative procedures by facilitating generator and lead mobilization, decreasing procedural difficulty, and decreasing the need for capsulectomy by >73% compared to implanting the device alone.2Catanzaro J.N. Bilchick K.C. Christopher T.J. et al.Implanting Cardiovascular Electronic Devices with A Biologic Tissue Envelope Improves Healing and Facilitates Reoperative Procedures.Circulation. 2022; 146A11052Google Scholar However, the outcome of implanting a biologic envelope within an existing fibrotic capsule was previously undocumented. This case report highlights the potential benefits of using a biologic device envelope during reoperative procedures. Histology confirmed that the biologic envelope had fully resorbed within the 5-month implantation period and was replaced by a layer of cellular and vascular host tissue, which simplified the subsequent reoperation by facilitating generator and lead mobilization, reducing procedural difficulty, and eliminating the need for any capsulectomy. Partial capsulectomy was performed during the first reoperative procedure, which may have supported the rapid transformation of the biologic envelope into the new cellular and vascular pocket tissue that we observed during the subsequent reoperation. Perhaps if no capsulectomy is performed in a fibrotic pocket prior to placement of a biologic envelope, the incisional site may still provide a sufficient host-scaffold interface and could result in the same outcomes, albeit over a slower period. However, further studies are needed to validate that hypothesis. Our results suggest that partial capsulectomy is sufficient to provide a productive interface for rapid tissue remodeling to occur, which lessens the risk of complications compared to performing full capsulectomy.7Gleva M.J. Poole J.E. Prevention of Cardiac Implantable Electronic Device Infections: Update and Evaluation of the Potential Role for Capsulectomy or the Antibiotic Pouch.J Atr Fibrillation. 2017; 9: 1540https://doi.org/10.4022/jafib.1540Crossref Scopus (7) Google Scholar,8Tarakji K.G. Krahn A.D. Poole J.E. et al.Risk Factors for CIED Infection After Secondary Procedures: Insights From the WRAP-IT Trial.JACC Clin Electrophysiol. 2022; 8: 101-111https://doi.org/10.1016/j.jacep.2021.08.009Crossref Scopus (11) Google Scholar Our findings provide the first histologic evidence that placing a biologic device envelope within an existing densely fibrotic capsule (with partial capsulectomy) can create a new cellular and vascular tissue layer within the pocket for the implanted device. When used in this manner, biologic envelopes may potentially mitigate some of the issues associated with reusing fibrotic implant pockets at device reoperation, potentially simplifying reoperations and decreasing complications, therefore improving long-term implant site health for patients. Additional clinical investigations are warranted to further explore the biological benefits of biologic device envelopes.
BibTeX
@inproceedings{srivastava2023rehabilitation,
author = {Ankur Srivastava and Hemal M. Nayak},
title = {{Rehabilitation of an existing device implant pocket using a biologic extracellular matrix envelope}},
booktitle = {HeartRhythm},
year = {2023},
doi = {10.1016/j.hrcr.2023.08.007},
}